Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2023-10-03 Director's Dealing
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2023-10-03 English
8-K
Transaction in Own Shares Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 28, 2023, by MAIA Biotechnology, Inc. The content focuses on the announcement of a board-approved share repurchase program allowing the company to buy back up to $800,000 of its common stock through September 2024. The document includes a press release as an exhibit and discusses the terms and conditions of the repurchase plan. There are no financial statements or detailed financial data presented, nor is this a full report like an annual or quarterly report. The primary subject is the company's capital activity related to share repurchases. According to the filing definitions, announcements about share repurchase programs fall under "Transaction in Own Shares (POS)". Therefore, the correct classification is POS with high confidence.
2023-09-28 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 1, 2023, by MAIA Biotechnology, Inc. It announces the entry into a material definitive agreement, specifically an 'at-the-market' sales agreement for offering and selling common stock up to $7 million. The document details the terms of the sales agreement, commission rates, and includes exhibits such as the sales agreement and legal opinion. There are no financial statements or quarterly/annual financial results presented. The content focuses on a capital raising transaction and financing activity. Therefore, this filing fits the category of Capital/Financing Update (CAP). The document length (7605 characters) and detailed description of the financing agreement support this classification with high confidence.
2023-09-01 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement on Form S-3. It details an offering of common stock by MAIA Biotechnology, Inc. through an ATM Sales Agreement with ThinkEquity LLC. The content includes offering terms, risk factors, use of proceeds, dilution, plan of distribution, and legal matters. This type of document is a capital raising disclosure, specifically a prospectus supplement for a securities offering, which fits the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or any other report type but a financing-related filing. The document length is substantial and contains detailed offering information, not just an announcement or a brief notice, confirming it is a Capital/Financing Update.
2023-09-01 English
Regulatory Filings 2023
Regulatory Filings
2023-08-24 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It references a filing related to securities registration and does not contain financial statements, earnings data, or detailed report content. The document is short (1498 characters) and serves as a formal request related to a capital raising process rather than a report or announcement of financial results. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2023-08-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.